Sarepta Therapeutics
SRPT
343 hedge funds and large institutions have $6.48B invested in Sarepta Therapeutics in 2021 Q4 according to their latest regulatory filings, with 74 funds opening new positions, 113 increasing their positions, 98 reducing their positions, and 32 closing their positions.
131% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 32
46% more call options, than puts
Call options by funds: $279M | Put options by funds: $192M
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
15% more repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 98
12% more funds holding
Funds holding: 306 → 343 (+37)
6% more capital invested
Capital invested by funds: $6.08B → $6.48B (+$393M)
0.2% more ownership
Funds ownership: 82.41% → 82.61% (+0.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$86M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$71M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$68.8M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$57.9M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$53.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$235M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$107M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$59.4M |
| 4 |
JP Morgan Chase
New York
|
-$39.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$38.9M |
SRPT Hedge Fund Activity: Q4 2021 in Review
343 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2021, worth a combined $6.48B — up 6.5% from $6.08B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new SRPT positions and 32 closed out — a net gain of 42 holders — while 113 added to existing stakes and 98 trimmed.
The largest buyer was Alkeon Capital Management, adding an estimated $86M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $235M sold.
- 343 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2021, up from 306 in Q3 2021.
- Funds reported $6.48B of Sarepta Therapeutics stock for Q4 2021, up 6.5% quarter-over-quarter.
- 74 funds opened new Sarepta Therapeutics positions in Q4 2021 and 32 closed out, a net change of +42 holders.
- The largest Sarepta Therapeutics buyer in Q4 2021 was Alkeon Capital Management, an estimated $86M added.
- The largest Sarepta Therapeutics seller in Q4 2021 was Capital Research Global Investors, an estimated $235M sold.
Based on aggregated 13F filings for Q4 2021.